UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Midazolam microdosing applied in early clinical development for drug–drug interaction assessment

British journal of clinical pharmacology, 2021-01, Vol.87 (1), p.178-188

2021

Volltextzugriff (PDF)

Nongenomic Steroid Action: Controversies, Questions, and Answers

Physiological reviews, 2003-07, Vol.83 (3), p.965-1016

2003

Volltextzugriff (PDF)

Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis

ERJ open research, 2022-10, Vol.8 (4), p.240

2022

Volltextzugriff (PDF)

Pharmacokinetics, Safety, and Tolerability of the Novel Chymase Inhibitor BAY 1142524 in Healthy Male Volunteers

Clinical pharmacology in drug development, 2019-05, Vol.8 (4), p.467-479

2019

Volltextzugriff (PDF)

INVESTIGATION OF PHARMACOKINETIC DRUG-DRUG INTERACTION FOLLOWING ORAL ADMINISTRATION OF BI 409306 AND DONEPEZIL IN HEALTHY SUBJECTS

Alzheimer's & dementia, 2017-07, Vol.13 (7), p.P935-P935

2017

Volltextzugriff (PDF)

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Nature (London), 2020-10, Vol.586 (7830), p.594-599

2020

Volltextzugriff (PDF)

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

Nature (London), 2021-07, Vol.595 (7868), p.572-577

2021

Volltextzugriff (PDF)

1585-P: MAFLD in Obesity with Deteriorating Glucose Control

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

A randomized phase I study of BI 1820237, a novel neuropeptide Y receptor type 2 agonist, alone or in combination with low-dose liraglutide in otherwise healthy men with overweight or obesity

Diabetes, obesity & metabolism, 2024-10

2024

Volltextzugriff (PDF)

Bioequivalence of macitentan and tadalafil given as fixed‐dose combination or single‐component tablets in healthy subjects

British journal of clinical pharmacology, 2020-12, Vol.86 (12), p.2424-2434

2020

Volltextzugriff (PDF)

PHARMACOKINETICS OF SINGLE AND MULTIPLE RISING DOSES OF BI 425809, A NEW GLYT1 INHIBITOR, IN YOUNG AND ELDERLY HEALTHY VOLUNTEERS

Alzheimer's & dementia, 2016-07, Vol.12 (7), p.P425-P425

2016

Volltextzugriff (PDF)

[P3–014]: INVESTIGATION OF PHARMACOKINETIC DRUG‐DRUG INTERACTION FOLLOWING ORAL ADMINISTRATION OF BI 409306 AND DONEPEZIL IN HEALTHY SUBJECTS

Alzheimer's & dementia, 2017-07, Vol.13 (7S_Part_19)

2017

Volltextzugriff (PDF)

Challenges in the Development of Intravenous Neurokinin‐1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose‐Finding, Phase 1 Study of Intravenous Fosnetupitant

Clinical pharmacology in drug development, 2022-12, Vol.11 (12), p.1405-1418

2022

Volltextzugriff (PDF)

Pharmacokinetics, Safety, and Tolerability of the α2C‐Adrenoreceptor Antagonist BAY 1193397 in Healthy Male Subjects

Clinical pharmacology in drug development, 2022-03, Vol.11 (3), p.296-308

2022

Volltextzugriff (PDF)

Pharmacokinetics, Safety, and Tolerability of the α 2C -Adrenoreceptor Antagonist BAY 1193397 in Healthy Male Subjects

Clinical pharmacology in drug development, 2022-03, Vol.11 (3), p.296-308

2022

Volltextzugriff (PDF)

Pharmacokinetic Interaction between Faldaprevir and Cyclosporine or Tacrolimus in Healthy Volunteers: A Prospective, Open‐Label, Fixed‐Sequence, Crossover Study

Basic & clinical pharmacology & toxicology, 2018-07, Vol.123 (1), p.84-93

2018

Volltextzugriff (PDF)

Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics

Clinical drug investigation, 2018-08, Vol.38 (8), p.737-750

2018

Volltextzugriff (PDF)

Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers

British journal of clinical pharmacology, 2021-04, Vol.87 (4), p.1824-1838

2021

Volltextzugriff (PDF)

Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects

Clinical drug investigation, 2019-12, Vol.39 (12), p.1223-1232

2019

Volltextzugriff (PDF)

Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial

SpringerPlus, 2014-07, Vol.3 (1), p.389-389, Article 389

2014

Volltextzugriff (PDF)

Dalteparin dose-dependently increases ROTEM® thrombelastography parameters only at supratherapeutic anti-factor Xa levels: An in vitro study

Clinical and experimental pharmacology & physiology, 2011-11, Vol.38 (11), p.783-786

2011

Volltextzugriff (PDF)

Effect of faldaprevir on raltegravir pharmacokinetics in healthy volunteers

Journal of clinical pharmacology, 2015-04, Vol.55 (4), p.384-391

2015

Volltextzugriff (PDF)

Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Nature (London), 2021-02, Vol.590 (7844), p.E17-E17

2021

Volltextzugriff (PDF)

Dalteparin dose-dependently increases ROTEM® thrombelastography parameters only at supratherapeutic anti-factor Xa levels: An in vitro study: Dalteparin increases ROTEM® parameters

Clinical and experimental pharmacology & physiology, 2011-11, Vol.38 (11), p.783-786

2011

Volltextzugriff (PDF)

P1‐061: Pharmacokinetics of Single and Multiple Rising Doses of BI 425809, A New Glyt1 Inhibitor, in Young and Elderly Healthy Volunteers

Alzheimer's & dementia, 2016-07, Vol.12 (7S_Part_8), p.P425-P425

2016

Volltextzugriff (PDF)

1 – 25 von 92

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(78)
Mit Volltextzugriff
(78)

Publikationsform

Sprache

Englisch
(86)
Deutsch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(56)
Life Sciences & Biomedicine
(45)
Humans
(25)
Male
(19)
Animals
(16)
Pharmacology & Pharmacy
(12)
Adult
(11)
Female
(10)
Biological And Medical Sciences
(8)
Biochemistry & Molecular Biology
(7)
Middle Aged
(7)
Pharmacokinetics
(7)
Young Adult
(7)
Fundamental And Applied Biological Sciences. Psychology
(6)
Original
(6)
Reward
(6)
Adolescent
(5)
Cell Biology
(5)
Endocrinology & Metabolism
(5)
Healthy Volunteers
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Midazolam microdosing applied in early clinical development for drug–drug interaction assessment

Nongenomic Steroid Action: Controversies, Questions, and Answers

Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis

Pharmacokinetics, Safety, and Tolerability of the Novel Chymase Inhibitor BAY 1142524 in Healthy Male Volunteers

INVESTIGATION OF PHARMACOKINETIC DRUG-DRUG INTERACTION FOLLOWING ORAL ADMINISTRATION OF BI 409306 AND DONEPEZIL IN HEALTHY SUBJECTS

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

1585-P: MAFLD in Obesity with Deteriorating Glucose Control

A randomized phase I study of BI 1820237, a novel neuropeptide Y receptor type 2 agonist, alone or in combination with low-dose liraglutide in otherwise healthy men with overweight or obesity

Bioequivalence of macitentan and tadalafil given as fixed‐dose combination or single‐component tablets in healthy subjects

PHARMACOKINETICS OF SINGLE AND MULTIPLE RISING DOSES OF BI 425809, A NEW GLYT1 INHIBITOR, IN YOUNG AND ELDERLY HEALTHY VOLUNTEERS

[P3–014]: INVESTIGATION OF PHARMACOKINETIC DRUG‐DRUG INTERACTION FOLLOWING ORAL ADMINISTRATION OF BI 409306 AND DONEPEZIL IN HEALTHY SUBJECTS

Challenges in the Development of Intravenous Neurokinin‐1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose‐Finding, Phase 1 Study of Intravenous Fosnetupitant

Pharmacokinetics, Safety, and Tolerability of the α2C‐Adrenoreceptor Antagonist BAY 1193397 in Healthy Male Subjects

Pharmacokinetics, Safety, and Tolerability of the α 2C -Adrenoreceptor Antagonist BAY 1193397 in Healthy Male Subjects

Pharmacokinetic Interaction between Faldaprevir and Cyclosporine or Tacrolimus in Healthy Volunteers: A Prospective, Open‐Label, Fixed‐Sequence, Crossover Study

Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics

Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers

Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects

Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial

Dalteparin dose-dependently increases ROTEM® thrombelastography parameters only at supratherapeutic anti-factor Xa levels: An in vitro study

Effect of faldaprevir on raltegravir pharmacokinetics in healthy volunteers

Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Dalteparin dose-dependently increases ROTEM® thrombelastography parameters only at supratherapeutic anti-factor Xa levels: An in vitro study: Dalteparin increases ROTEM® parameters

P1‐061: Pharmacokinetics of Single and Multiple Rising Doses of BI 425809, A New Glyt1 Inhibitor, in Young and Elderly Healthy Volunteers

Suchergebnisse filtern